Yole Développement Announces Foundation of BLUMORPHO
News Feb 17, 2015
Yole Développement (Yole) announces the founding of daughter company, BLUMORPHO SAS. BLUMORPHO’s mission is to create value from all forms of innovation.
BLUMORPHO is developing businesses for its customers by building a dynamic marketplace and is active all along the innovation chain, from research to market.
The spin-off will undertake Yole Finance Innovation activities dedicated to supporting technology exploitation, young companies’ maturation and intellectual property portfolio optimization.
“BLUMORPHO is operating an innovative business model in marketing a portfolio of attractive technologies to serve industrial needs and demand”, explains Géraldine Andrieux Gustin, CEO & Co-founder of BLUMORPHO. “We facilitate access to technologies and innovations with added value for industrial companies. Based on Yole’s expertise, and our hands-on experience, we identify bankable challenges in different industries and we match them with relevant solutions and technologies to address those needs. As a trusted third party active throughout the ecosystem, BLUMORPHO supports successful innovation processes”, she adds.
The concept of this new business model has been tested and validated in the course of COWIN, which was initiated and led by Géraldine as Yole Finance’s Senior Partner. Sponsored by the European Commission, COWIN was dedicated to facilitating the commercial exploitation of results from European research projects on smart systems. From 2010 to 2014, COWIN generated about 25 million Euros’ worth of investment opportunities in technology exploitation.
“The launch of BLUMORPHO is a natural continuation of COWIN. BLUMORPHO will contribute to maintaining COWIN’s momentum by working in close collaboration with European technology owners engaged in driving their innovations to market,” highlighted BLUMORPHO’s CEO & Co-founder.
By leveraging an organ-on-a-chip model and a bioreactor, four human gut metabolites have been identified that can help explain the enhanced sensitivity of the human colon towards enterohemorrhagic E. coli, which is responsible for more than 100,000 infections per year in the USA alone.READ MORE